At the upcoming ASCO conference, Mabwell (Shanghai) Bioscience will present the Phase I/II clinical study results of 9MW2821 for several advanced solid tumors through an oral report.

Age-standardized rate refers to a statistical measure that allows for the comparison of health-related rates, such as disease incidence or mortality rates, between populations with different age structures.

May 10th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Blinatumomab, sold under the brand name Blincyto, is a breakthrough cancer treatment developed by Amgen Inc.

Context Therapeutics has received FDA approval for its IND application, initiating a Phase 1 clinical trial of CTIM-76.

Loncastuximab tesirine, marketed under the brand name Zynlonta, is a targeted antibody-drug conjugate (ADC) developed by ADC Therapeutics SA.

Remix Therapeutics has started dosing the first participants in a pair of Phase 1 studies. These trials are testing REM-422 in treating Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS).

JSKN003 is a novel ADC targeting two distinct epitopes of HER2, independently developed by Alphamab Biopharmaceuticals utilizing its proprietary glycan-based site-specific conjugation platform.

Alpha-9 Oncology reports initial dosing of the first participant in a phase 1 trial for A9-3202, targeting locally advanced or metastatic melanoma patients.

Inebilizumab-cdon, commercially known as Uplinza, is an innovative immunomodulatory agent developed by Viela Bio, now a part of Horizon Therapeutics USA.

Atsena Therapeutics Reveals Encouraging Results from Initial Group in Phase 1/2 Study of ATSN-201 Gene Treatment for X-linked Retinoschisis (XLRS).

Medilink Therapeutics will present preliminary results from the first human clinical Phase 1 trial of YL202 for the treatment of locally advanced or metastatic non-small cell lung cancer and breast cancer (NCT05653752).